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DNA fragments released from cancer cells into the
blood can be used to generate molecular profiles of
tumors. Non-invasive 'liquid biopsies' can be used to
monitor minimal residual disease and detect the
emergence of drug resistance.cfDNA has improved rapidly, thanks to enhancements inIntroduction
Precision oncology relies on the availability of accurate
molecular profiles of individual tumors, which are cur-
rently determined by genetic analysis of DNA extracted
from neoplastic tissue. Sampling tumor tissue from sur-
gical specimens or biopsies has significant limitations.
Biopsies provide a single snapshot in time, are subject to
selection bias resulting from tumor heterogeneity, can
lead to severe clinical complications and can be difficult to
obtain [1-3]. Tumor cells release DNA into the blood, and
this offers the opportunity to determine the genetic land-
scapes of solid cancer from the circulation, an approach
commonly called 'liquid biopsy'. Here, we summarize ap-
plications of liquid biopsies to interrogate cancer genomics
in the blood of patients in different clinical scenarios.
Liquid biopsies, an evolving concept
In 1948, Mandel and Métais described the presence of
circulating, cell-free nucleic acids (cfNAs) in human
blood for the first time [4]. In 1977, further studies
showed that cancer patients had higher plasma levels of
circulating DNA than healthy controls [5], and Stroun
and colleagues showed that circulating DNA shared
some biophysical properties (such as decreased strand sta-
bility) with the DNA within cancer cells, thus suggesting
that cfNA was of tumor origin [6] (Figure 1). At that time,
these seminal findings attracted little attention in the
scientific community. In 1994 the breakthrough finding of* Correspondence: alberto.bardelli@ircc.it
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patients turned the spotlight on cfDNA once again [7,8].
In 1996, microsatellite alterations in cfDNA were reported
in cancer patients [9,10] and over the past two decades
several types of cfNAs (such as DNA, mRNA and micro-
RNAs) have been detected in the blood of cancer patients
(Figure 1) [11-13]. In recent years, our ability to analyze
technologies that enable detection of mutant alleles with
very high specificity and sensitivity. The latest develop-
ment involved applications of next-generation sequencing
to tumor cfDNA, which allows mutational profiling of the
entire coding sequence (exome) of cancer cells from the
blood [14].
Significantly higher cfDNA concentrations are present
in serum than in plasma [15-20]. The increased level of
cfDNA in serum is due to the clotting of white blood
cells in the collection tube, leading to their lysis [17,19,20].
As a consequence, cfDNA in serum is 'diluted' by genomic
DNA released from white blood cells. Accordingly, plasma
is a better source of specific tumor cfDNA [21,22].
In general, concentrations of cfNAs are higher in indi-
viduals with cancer than in healthy controls, and levels
are further increased in metastasis. Both tumor-derived
and normal germline cfNAs are released into the blood,
and the proportion of tumor-derived cfNA is broadly
related to the extent of the disease [1]. The amount of
cfNA is also influenced by clearance, degradation and other
physiological filtering events in the blood and lymphatic
circulation [23-25]. Nucleic acids are cleared from the
blood by the liver and kidneys and have a variable half-life
in the circulation, ranging from 15 minutes to several
hours [23]. The release of nucleic acids into the blood is
not fully understood but is probably related to the fast
turnover of cancer cells and the ensuing apoptosis or
necrosis [24,25]. Numerous studies show that virtually
all living cells actively release DNA fragments [26]. The
presence of DNA and RNA in exosomes, vesicles that
are actively released by multiple cell types (including
neoplastic cells), is also well documented [27-29].d Central Ltd. The licensee has exclusive rights to distribute this article, in any
n. After this time, the article is available under the terms of the Creative Commons
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1948: cfDNA discovery by Mandel and Metais [4]
1977: cfDNA concentration is significantlyincreased in cancer patients [5]
1989: Mechanisms of cfDNA releasing are revealed
and the concept of “liquid biopsy” is developed [6]
1994:
Amplification of tumor associated oncogene and RAS gene 
mutations are detected in cfDNA isolated from patient
with leukemia and pancreatic cancer [7, 8]
1996:
Microsatellite alterations in cell-free DNA are shown
in cancer patients [9, 10]
1997-1999:
cfDNA tumor-associated alterations are detected
in patients affected by many different cancer






APC mutations are followed to monitor tumor
dynamics in colorectal cancer patients [40]
2009:
EGFR T790M mutation is detected in cfDNA of lung
cancer patient and associated with acquired resistance
to targeted therapy [51]
2012:
First mechanisms of acquired resistance to therapy
discovered directly in blood of colorectal cancer patients
[52]
2013: cfDNA whole exome sequencing analysis of cfDNA in patients
with acquired resistance to cancer therapy [14]
Figure 1 Timeline of discoveries in cell-free DNA. The references mentioned are [4-14,40,51,52].
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(which corresponds to 3 × 1010 cancer cells), may release
up to 3.3% of the DNA present in the cancer cells into
the blood every day [30]. The size of tumor cfDNAs de-
tected in the blood of cancer patients is highly variable:
most are 70 to 200 base pairs long but fragments of up
to 21 kilobases have also been detected [31]. In patients,
the amount of cfDNA ranges between 0 and >1,000 ng/ml
of blood, with an average of 180 ng/ml [32-35]. Monitoring
cfDNA concentrations per se does not seem to be useful
for diagnostic purpose because several physiological and
pathological conditions besides cancer can lead to great
changes in cfDNA levels. For instance, pro-inflammatory
diseases, such as liver cirrhosis, hepatitis, systemic lupus
erythematous or rheumatoid arthritis [36,37], all lead to
the release of high levels of cfDNA.
In a recent study, levels of tumor cfDNA were evalu-
ated in 410 patients with solid tumors [38]. The fraction
of patients with detectable levels of cfDNA varied among
tumor types. Most patients with stage III ovarian or liver
cancer, as well as most patients with neuroblastoma or
melanoma, had measurable levels of cfDNA. In addition,most patients with metastatic cancers of the pancreas,
bladder, colon, stomach, breast, liver, esophagus or head
and neck had measurable levels of cfDNA. Notably, less
than 50% of the patients with medulloblastomas or
metastatic cancers of the kidney, prostate or thyroid,
and less than 10% of patients with gliomas harbored
detectable cfDNA. A likely explanation for the low amount
of cfDNA in patients with tumors localized to the cen-
tral nervous system is the presence of the blood-brain
barrier [38].
Molecular profiles of solid cancer from cfDNA
Defining the tumor genotype of an individual patient is
becoming part of the standard of care for a significant
proportion of cancer patients. Genotyping can be used
in several settings: to categorize the type and the stage
of cancer, to establish the aggressiveness of the disease,
to tailor treatment and to monitor evolution of the
cancer during therapy.
Currently, the genotype of a tumor is established from
tumor tissue, which is obtained through surgically or
radiologically guided biopsies. However, sampling tumor
Siravegna and Bardelli Genome Biology 2014, 15:449 Page 3 of 6
http://genomebiology.com/2014/15/8/449tissue in this way has significant, inherent limitations. Mo-
lecular profiling of tumor tissue provides a single snapshot
in time, is subject to selection bias owing to tumor hetero-
geneity and does not capture the complexity of the disease
if multiple metastatic lesions are present [1-3,39].
When a comprehensive analysis of the overall disease is
required or when tissue specimens are difficult to obtain
or are unavailable, liquid biopsies are an attractive alter-
native option. This is because circulating tumor DNA
fragments contain identical genetic defects to those in the
tumors themselves and virtually all cancer-related molecu-
lar alterations can be detected in cfDNA. These include
somatic point mutations, loss of heterozygosity (LOH),
translocations, gene copy number changes and DNA
methylation changes. For example, oncogenic alterations
such as mutations in KRAS (Kirsten rat sarcoma viral
oncogene homolog), BRAF (B-Raf proto-oncogene, serine/
threonine kinase), PIK3CA (phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha) and EGFR
(epidermal growth factor receptor) can be readily detected
in the blood of patients with lung, colorectal, breast or
pancreatic cancer, or melanoma. Mutations that inactivate
common tumor suppressor genes such as APC (adenoma-
tous polyposis coli) and TP53 (tumor protein p53) have
also been detected in the plasma of cancer patients
[30,40]. Gene copy number variations, such as amplifi-
cation of EGFR, HER2 (human epidermal growth factor
receptor 2) and MET (MET proto-oncogene, receptor
tyrosine kinase), can also be detected in the blood [41-44].
Any tumor-specific molecular alteration can be detec-
ted in the blood of patients with cancer, and profiling of
cfDNAs from plasma or serum has been proposed for
several clinical applications (Figure 2), the most promising
of which we discuss in the following sections.
Clinical applications of liquid biopsies
Monitoring minimal residual disease
Surgery with curative intent is used for many cancer
patients. A central question is whether further therapy is
needed after surgical removal of the cancer. Currently,
predicting which patients are disease-free after surgery
(cured) and those who have residual disease depends
largely on clinical and pathological parameters (mainly
the tumor-node-metastasis staging system). There is
currently no effective diagnostic means to distinguish
between those patients that are disease-free and those
with minimal residual disease that cannot be detected by
clinical examination or imaging. Undetected, untreated
minimal residual disease gives rise to recurrences. As a
result, patients with high-risk clinical and pathological
criteria are indiscriminately treated with adjuvant che-
motherapy. Unfortunately, this therapy is frequently not
needed because the patient would have been cured with
surgery and/or radiotherapy alone.Liquid biopsies have great potential in this scenario.
The detection of tumor cfDNA following surgery/radio-
therapy would be an indicator of residual disease, and
hence liquid biopsies could be used to identify those
patients who would benefit from adjuvant therapy while
sparing those who would not benefit from unnecessary
treatment. Detection of tumor cfDNA after completion of
surgery/radiotherapy would indicate the presence of
micro-metastasis and much greater risk of relapse, indicat-
ing a need for adjuvant therapy. Moreover, the detection
of tumor cfDNA would indicate early relapse and could
potentially be used to tailor targeted therapy to the patient
[45] (Figure 2).
Recently, Beaver and colleagues [46] studied tumor
cfDNA to detect PIK3CA mutations and to monitor
residual disease after surgery in patients with early stage
breast cancer. Primary breast tumors and matched pre-
and post-surgery blood samples were collected from early-
stage breast cancer patients. The study was conducted
prospectively, which adds considerable relevance to the
findings. Droplet digital PCR (ddPCR) was used to assess
the presence of PIK3CA mutations (in exon 9 and 20) in
the blood of estrogen-receptor- and progesterone-recep-
tor-positive early-stage breast cancer patients. DNA ex-
tracted from 30 tumor samples was analyzed by Sanger
sequencing for common PIK3CA mutations; 10 samples
were found to carry PIK3CA mutations. The same 30
samples were analyzed by ddPCR, which identified five
more patients carrying PIK3CA mutations. Plasma cfDNA
was then isolated from pre- and post-operative blood
samples. In 14 of the 15 samples with mutations, those
mutations were detected in pre-surgery plasma samples
by ddPCR, whereas no mutations were found in the pre-
surgery samples in which post-surgery samples showed
no mutations. The sensitivity and specificity of cfDNA
analysis to detect mutations were thus remarkable (93.3%
and 100%, respectively). Among 10 of the patients with
mutation-positive pre-surgery tumor cfDNA, analysis of
post-surgery plasma detected PIK3CA mutations in five.
These patients had no other clinical evidence of disease by
any radiological examination the patients were subjected
to. Overall, the work of Beaver and colleagues [46] pre-
sents the first evidence that a 'liquid biopsy' approach can
be used to identify patients with breast cancers at early
stages and at risk of recurrence after surgery.
Liquid biopsy can also be used to monitor tumor
dynamics in a cancer patient. For example, assessing the
fluctuations of an APC mutation, which is known to be
the initiating lesion in colorectal cancer tumorigenesis,
during the follow-up of a patient provides a measure of
the systemic tumor burden, because levels of the mutation
in circulating DNA decrease following surgery and in-
crease as new lesions appear (as detected by radiological
examination) [40].
(1) Diagnosis: genotyping circulating tumor cells 
(CTC) and cell-free DNA (cfDNA) in the blood to 





(5) Follow up: patient
monitoring throughout the treatment
course to assess response and resistance
(4) Treatment: analysis of cfDNA
and CTC for real time monitoring of
response to therapy
(2) Surgery: circulating tumor DNA and CTC
are not present, the patient is disease free 
(3) Minimal residual 
disease: circulating
tumor DNA and CTC 
are still present in
the circulation
Figure 2 Clinical applications of cell-free DNA analysis. cfDNA can be used in (1) diagnosis (2,3) to detect residual disease after surgery,
























Figure 3 Schematic representation of clonal evolution in
patients treated with anti-EGFR monoclonal antibodies. The
lines are examples of the likely levels of mutated cfDNA detected at
different stages of treatment. APC mutation (black line) reflects tumor
burden, which decreases after treatment but increases again when
resistance develops. Different KRAS and NRAS mutations (green, purple
and blue lines) are detected in cfDNA at the acquisition of resistance,
before relapse is clinically manifest.
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In the past decade, drugs that target genetically defined
tumor vulnerabilities (such as EGFR or BRAF mutations)
have shown remarkable effectiveness [47]. Acquired
resistance, which is observed in virtually all patients
following treatment with anticancer drugs, limits the
utility of these drugs and is a substantial challenge to the
clinical management of cancer patients. Accordingly,
understanding the molecular basis and development
of acquired resistance is key to trying to overcome it.
Analysis of tumor cfDNA provides a valuable opportunity
to repeatedly monitor molecular response during targeted
treatment and detect early evidence of emerging resist-
ance (such as specific mutations) and tumor recurrence,
as described below [14,40,48-50].
Tracking the genomic evolution of cancer during ther-
apy is an unmet clinical need. As discussed above, tissue
biopsies reveal only a fraction of the overall disease het-
erogeneity, especially in patients with metastatic disease.
It is fair to say that no effective means currently exists
to assess the molecular evolution of the overall disease
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metastatic lesions in distinct organs.
In contrast, tumor cfDNA analysis enables early identifi-
cation of molecular changes associated with drug resistance
and can be easily repeated multiple times in one patient.
Analysis of tumor cfDNA in plasma samples obtained
before and after treatment can be used to provide a
global picture of the molecular genetics of a patient's
tumor. This molecular picture includes dynamic changes
in the mutation profile that occur during therapy, as well
as the heterogeneity that emerges as a result of therapeutic
selective pressure. Understanding the mechanisms of
acquired resistance to targeted agents at the molecular
level can be used to plan new therapeutic approaches with
drugs that will suppress the expansion of the clones that
are responsible for most of the current failures of medical
treatments. This knowledge could provide the early adop-
tion of alternative therapies before resistance is detected
and clinically manifest (Figure 3).
Conclusions and future directions
Liquid biopsies can improve the effectiveness of preci-
sion oncology, with potential benefits to patients and
healthcare systems. Research on liquid biopsies has seen
enormous development in the past 5 years; this has led
to a proliferation of publications, most of which involve
very small numbers of patients. None of these studies
presented definitive evidence as to how the analysis of
tumor cfDNA may be clinically relevant or applicable
[14,38,41-44,46,48-52]. What the field needs are well-
controlled clinical studies, involving extensive cohorts of
patients, in which liquid biopsies are used to address
clinically relevant questions. We propose that these stud-
ies should focus on two questions: the development of
non-invasive tests to detect minimal residual disease in
patients affected by solid cancers; and the use of liquid
biopsies to monitor the emergence of molecular resistance
to anticancer therapies before relapse is clinically manifest.
This could lead to the early adoption of further lines of
therapy.
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